5.2 Nieuw advies
Eltrombopag is geïndiceerd voor gebruik bij volwassen patiënten met verworven ernstige aplastische anemie die niet in aanmerking komen voor hemopoëtische stamceltransplantatie en die een ontoereikende respons hebben op intensieve immunosuppressieve therapie respectievelijk die een terugval hebben na eerdere immunosuppressieve therapie.
6
Literatuur
1 Aplastic anemia and MDS International Foundation. About bone marrow failure. 2013
2 Dolberg OJ, Levy Y. Idiopathic aplastic anemia: diagnosis and classification. Autoimmun Rev 2014, 13, 569-573
3 Killick SB, Bown N et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 2016 Jan;172(2):187-207. doi: 10.1111/bjh.13853. Epub 2015 Nov 16.
4 Rovo A, Tichelli A et al. Diagnosis of acquired aplastic anemia. Bone Marrow Transplant 2013: 48, 162-167
5 Dezern AE, Sekeres M et al. The challenging world of cytopenias:
distinguishing myelodysplastic syndromes from other disorders of marrow failure. Oncologist 2014: 19, 735-45
CHMP Variation Assessment Report on Revolade® (eltrombopag) in the treatment of adult patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy.
EMA/CHMP/598426/2015. 25 juli 2015. 6
7 Huisman C, Groot de MR, Broers AEC et al. Richtlijn ‘Diagnostiek en
behandeling van verworven aplastische anemie bij volwassenen’ Richtlijnen nr 6, sept 2013.
8 Kaufman, DW, Kelly JP et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Hematol 1996, 57, 23-30.
9 Montane E, Ibanez L et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica 2008, 93, 518-523
10 Cesaro S, Marsh J et al. Retrospective survey on the prevalence and outcome of prior autoimmune diseases in patients with aplastic anemia reported to the registry of the European group for blood and marrow transplantation. Acta haematological 2010;124(1):19-22)
11 website NVvH, http://www.hematologienederland.nl/aplastische-anemie-nvvh 12 Valdez JM, Scheinberg P et al. Decreased infection-related mortality and
improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis 2011, 52, 726-735
13 Marsh JC, Kulasekararaj AG. Management of the refractory aplastic anemia patient: what are the options? Blood 2013 Nov 21;122(22):3561-7. doi: 10.1182/blood-2013-05-498279. Epub 2013 Sep 19.
14 Quarello P, Saracco P et al. Epidemiology of infections in children with acquired aplastic anaemia: a retrospective multicenter study in Italy. Eur J Haematol 2012, 88, 526-534.
15 Park YB, Lee JW et al. Incidence and etiology of overt gastrointestinal bleeding in adult patients with aplastic anemia. Dig Dis Sci 2010, 55, 73-81
16 Erickson-Miller CL, Delorme E et al. Preclinical activity of eltrombopag (SB- 497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009, 27, 424-30
17 Jeong DC, Chung NG et al. Epidemiology and clinical long-term outcome of childhood aplastic anemia in Korea for 15 years: retrospective study of the Korean Society of Pediatric Hematology Oncology (KSPHO). J Pediatr Hematol Oncol 2011, 33, 172-178
18 Erhardt JA, Erickson-Miller CL et al. Comparative analyses of the small
molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 2009, 37, 1030-7
19 The myelodysplastic syndromes foundation Inc. Anemia, blood transfusions, iron overload, and myelodysplastic syndromes: a handbook for adult MDS
DEFINITIEF | Farmacotherapeutisch rapport eltrombopag (Revolade®) voor behandeling van patiënten met ernstige refractaire aplastische anemie bij wie geen HSCT mogelijk is | 14 maart 2016
patients. 2011
20 Takatoku M, Uchiyama T et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007, 78, 487-494
21 Storb R, Leisenring W et al. Long-term follow-up of allogeneic marrow
transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood 1997, 89, 3890-1
22 Horowitz MM. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol 2000, 37, 30-42
23 Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol 2007, 136, 549-564
24 Anasetti C, Doney KC et al. Marrow transplantation for severe aplastic anemia. Long-term outcome in fifty "untransfused" patients. Ann Intern Med 1986, 104, 461-6
25 Bacigalupo A, Brand R et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy-- The European Group for Blood and Marrow Transplantation experience. Semin Hematol 2000, 37, 69-80
26 Expert opinion Nederlandse Vereniging voor Hematologie, 8 maart 2016. 27 Dufour C, Svahn J et al. Severe aplastic anemia working party of the EBMT.
Front-line immunosuppressive treatment of acquired aplastic anemia. Bone Marrow Transplant 2013, 48, 174-7.
28 Tolar J, Sodani P et al. Alternative donor transplant of benign primary
hematologic disorders. Bone Marrow Transplant 2015 May;50(5):619-27. doi: 10.1038/bmt.2015.1. Epub 2015 Feb 9.
29 Scheinberg P, Nunez O et al. Activity of alemtuzumab monotherapy in treatment-naïve, relapsed, and refractory severe acquired aplastic anemia. Blood 2012;119:345-54
30 Scheinberg MD, Olga Nunez RN et al. Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia. N Engl J Med 2011;365:430-8 31 Brodsky RA, Chen AR et al, High dosed cyclophoshamide for severe aplastic
anemia: long term follow up. Blood 2010; 115:2136-2141 32 Expert opinion, 8 september 2015
33 Risitano AM, Perna F. Aplastic anemia: immunosuppressive therapy in 2010. Pediatr Rep. 2011 Jun 22; 3(Suppl 2): e7. Published online 2011 Jun 22. doi: 10.4081/pr.2011.s2.e7. PMCID: PMC3206528
34 Chuhjo T, Yamazaki H et al. Danazol therapy for aplastic anemia refractory to immunosuppressive therapy. Am J Hematol 2008, 83, 387-9
35 Scheinberg P, Nunez O et al. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 2006, 133, 606-11
36 Scheinberg P, Wu CO et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica 2009, 94, 348-54 Summary of Product Characteristics Revolade®. 24 september 2015
37
38 Townsley DM, Desmond R et al. Pathophysiology and management of
thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes. Int J Hematol 2013, 98, 48-55
39 Zeigler FC, Bennett BD et al. Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells. Blood 1994, 84, 2422-30
40 Alexander WS, Roberts AW et al. Studies of the c-Mpl thrombopoietin receptor through gene disruption and activation. Stem Cells 1996, 14 Suppl 1, 124-32.
41 Qian H, Buza-Vidas N et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell 2007, 1, 671-84.
42 Sun H, Tsai Y et al. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res 2012, 9, 77-86.
43 Desmond R, Townsley DM et al. Eltrombopag restores trilineage
hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 2014, 123, 1818-1825.
44 Zorginstituut Nederland. Farmacotherapeutisch rapport eltrombopag (Revolade®) bij de indicatie 'Immuun (Idiopathische) trombocytopenische purpura’. Diemen, 23 augustus 2010.
https://www.zorginstituutnederland.nl/binaries/content/documents/zinl- www/documenten/publicaties/geneesmiddelbeoordelingen/2010/1008- eltrombopag-revolade/1008-eltrombopag-
revolade/eltrombopag+%28Revolade%29.pdf
45 Scheinberg P, Townsley D et al. Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia. Am J Hematol 2014 May;89(5):467-9. doi: 10.1002/ajh.23669. Epub 2014 Mar 7. 46 NICE technology appraisal guidance [TA382] Eltrombopag for treating severe
aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal). Published date: January 2016.
http://www.nice.org.uk/guidance/ta382.http://www.nice.org.uk/guidance/ta3 82
47 Olnes MJ, Scheinberg P et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012, 367, 11-19
48 A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia (ELT112523).
https://www.clinicaltrials.gov/ct2/show/NCT00922883?term=NCT00922883&r ank=1
49 CHMP Assessment Report Revolade® eltrombopag for Chronic idiopathic thrombocytopenic purpura (ITP). EMA/CHMP/279276/2010. 29 april 2010. 50 CHMP variations assessment report on Revolade® (eltrombopag) in the
treatment of adult patients with HCV-associated thrombocytopenia. EMA/491212/2013. 25 juli 2013.
51 GIP databank, april 2015
52 Gafter-Gvili A, Ram R et al. Management of aplastic anemia: the role of systematic reviews and meta-analyses. Acta Haematol 2011, 125, 47-54 53 Shin, S. H. & Lee, J. W. 2013. The optimal immunosuppressive therapy for
aplastic anemia. Int J Hematol, 97, 564-572
54 Locasciulli, A., Oneto, R., Bacigalupo, A. et al. Severe aplastic anemia working party of the European, B. & Marrow Transplant, G. 2007. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica, 92, 11-8